by Undescended testicles occurs when one or both testes fail to descend from the abdomen into the scrotum. Often called “cryptorchidism”, the condition affects approximately 1 in 100 male newborns and is responsible for infertility if left untreated. Treatments involve surgery to bring down the testes into their normal position in the scrotum. Some boys are also prescribed hormone therapy with medications like human chorionic gonadotropin (hCG) to encourage natural descent of the testis before considering surgery. Growing awareness amongst parents about the importance of timely treatment for cryptorchidism is driving growing demand for surgical and pharmaceutical interventions in the global market.
The global Undescended Testicle Market is estimated to be valued at US$ 4.51 billion in 2023 and is expected to exhibit a CAGR of 7.3% over the forecast period 2023 to 2030, as highlighted in a new report published by CoherentMI.
Market Key Trends:
One of the key trends in the global undescended testicle market is rising adoption of minimally invasive surgical procedures. Traditionally, open surgery involving an incision in the scrotum was the standard approach to bring down undescended testes. However, minimally invasive procedures such as laparoscopic-assisted surgeries are gaining popularity due to benefits such as less post-operative pain, fewer complications, shorter hospital stay and better cosmetic outcomes. These advanced techniques are being driven by technological developments in medical devices and growing expertise of urologists. Another notable trend is increasing research on pharmaceutical therapies that can help induce natural testicular descent without surgery. While hCG injections are currently used, companies are conducting clinical trials on new drug candidates that may offer better efficacy and success rates at lowering undescended testicles. This could provide an alternate first-line treatment approach and further fuel the growth of the market.
Porter’s Analysis:
Threat of new entrants: Low capital requirement and less economies of scale make the threat of new entrants moderate in the global undescended testicle market. However, established brands and regulations restrict new players.
Bargaining power of buyers: Large number of players and availability of generic drugs increase bargaining power of buyers in the global undescended testicle market.
Bargaining power of suppliers: Established distribution channels and dependence of players on few suppliers increase bargaining power of suppliers in the global undescended testicle market.
Threat of new substitutes: Limited substitutes and focus on innovation makes threat of new substitutes low in the global undescended testicle market.
Competitive rivalry: Large number of global and regional players and potential new entrants intensify competitive rivalry in the global undescended testicle market.
Key Takeaways:
The global Undescended Testicle Market Size is expected to witness high growth. The global Undescended Testicle Market is estimated to be valued at US$ 4.51 billion in 2023 and is expected to exhibit a CAGR of 7.3% over the forecast period 2023 to 2030.
North America dominates the global undescended testicle market due to high healthcare expenditure and increasing awareness. Asia Pacific is expected to grow at the fastest pace during the forecast period owing to increasing healthcare facilities and rising medical tourism in the region.
Key Players :
Key players operating in the global undescended testicle market are Ferring Pharmaceuticals, Pfizer, Eli Lilly and Company, Sanofi, Merck & Co., Bayer AG, Endo International, AstraZeneca, Johnson & Johnson, Takeda Pharmaceutical. Focus on research and development and product innovation are the key strategies adopted by major players to gain competitive edge in the global undescended testicle market.
*Note:
1.Source: CoherentMI, Public sources, Desk research
2.We have leveraged AI tools to mine information and compile it
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc.
